Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD19 specificity or anti-CD3 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.
There are currently no customer reviews or questions for Recombinant Human Anti-CD19 x Human Anti-CD3 Bispecific Antibody (scFv-Fc) (BSCFV-H218). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS